SmithKline

CDRD, CDRD Ventures, GSK collaborate to advance Canadian health research

Friday, June 1, 2012 03:07 PM

The Centre for Drug Research and Development (CDRD), its commercial arm, CDRD Ventures (CVI), and global pharmaceutical company GlaxoSmithKline (GSK) in have entered into a strategic collaboration that will provide new financial resources as well as leading drug development expertise to be applied to the development and commercialization of health research conducted in Canadian research institutions.

More... »

Stiefel to acquire psoriasis topical agent from Welichem Biotech

Thursday, May 31, 2012 02:24 PM

Stiefel, a subsidiary of GlaxoSmithKline, has signed an agreement with Canada-based Welichem Biotech to acquire exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.

More... »

GSK and HKCF establish Cancer Drug Relief Fund in Hong Kong

Wednesday, May 30, 2012 02:48 PM

In a joint effort, GlaxoSmithKline and Hong Kong Cancer Fund have established the Cancer Drug Relief Fund, a $5.4 million three-year pilot project dedicated to offering financial assistance by way of subsidized cancer drugs to low income patients and those in the “sandwich class.”

More... »

Innovative public-private collaboration to tackle antibiotic research

Friday, May 25, 2012 01:05 PM

AstraZeneca and GlaxoSmithKlinehas welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics.

More... »

Auxilium and GSK to co-promote Testim in U.S.

Monday, May 21, 2012 12:35 PM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company based in Malvern, Penn., and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc, have entered into an agreement for the co-promotion of Auxilium’s Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.

More... »

GlaxoSmithKline to fully acquire Cellzome for $97.2 million

Wednesday, May 16, 2012 10:47 AM

GlaxoSmithKline has entered into an agreement with Cellzome, a privately-held chemical proteomics company, to acquire all shares in the company it does not currently own for $99 million in cash. Cellzome, which has laboratories in Cambridge, U.K., and Heidelberg, Germany, will become part of GSK's R&D organization.

More... »

GSK offers $13 per share for HGS

Wednesday, May 9, 2012 11:46 PM

GlaxoSmithKline will not participate in Human Genome Sciences’ strategic alternatives review process and will instead commence a tender offer this week to acquire all outstanding shares of HGS for $13.00 per share in cash.

More... »

GSK adds two non-executive directors to its board

Friday, May 4, 2012 08:00 AM

GlaxoSmithKline (GSK) has appointed Lynn Elsenhans and Jing Ulrich as non-executive directors to the company’s board, beginning July 1, 2012.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

HGS refuses GSK unsolicited offer, considers alternatives

Friday, April 20, 2012 11:21 AM

Human Genome Sciences has refused GlaxoSmithKline’s unsolicited offer on April 11 proposing to acquire all of the outstanding shares of HGS for $13.00 per share in cash ($2.6 billion), an 81% premium to closing share price on April 18.

More... »